TP53 and serous adenocarcinoma: The frequency of aberrant mutation-type p53 staining in these cases (36%) 112 is comparable with that reported in conventional clear cell carcinoma (33%–38%) 44,47,58,59, and substantially less than that expected in serous carcinoma.